OSE:ULTI
Ultimovacs ASA Stock Company Profile
kr9.00
+0.310 (+3.57%)
At Close: May 31, 2024
Information
Ullernchausséen 64
Oslo 0379
47 41 38 00 80
ultimovacs.com
Industry: Biotechnology
Sector: Healthcare
Description
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
